


Amendments to the Claims:

Claim 1. (Currently amended): Use A method for the treatment of myocardial infarction, myocardial ischaemia, coronary vasospasm, angina and cardiac failure which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I):



in which:

- R₁ represents a halogen or a CF₃, (C₁-C₄)alkyl or (C₁-C₄)alkoxy group;
- Y represents a nitrogen atom ~~or a CH group~~;
- Z' and Z'' each represent hydrogen or a (C₁-C₃) alkyl group, or one represents hydrogen and the other a hydroxy group, or both, together, represent an oxo group;
- Z represents
 - ♦ a phenyl radical;
 - ♦ a phenyl radical monosubstituted with a substituent X, X being
 - a) a (C₁-C₆)alkyl; (C₁-C₆)alkoxy; (C₃-C₇)carboxyalkyl; (C₁-C₄)alkoxycarbonyl(C₁-C₆)alkyl; (C₃-C₇)carboxyalkoxy or (C₁-C₄)alkoxycarbonyl(C₁-C₆)alkoxy group;
 - b) a group selected from a (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkyloxy, (C₃-C₇)cycloalkylmethyl, (C₃-C₇)cycloalkylamino and cyclohexenyl group, it being possible for said group to be substituted with a halogen, hydroxy, (C₁-C₄)alkoxy, carboxy, (C₁-C₄)alkoxycarbonyl, amino, mono- or di-(C₁-C₄)alkylamino;
 - c) a group selected from a phenyl, phenoxy, phenylamino, N-(C₁-C₃)alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl or styryl, it being possible for said group to be mono- or poly-substituted on the phenyl group with a halogen, CF₃, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, cyano, amino, mono- or di-(C₁-C₄)alkylamino, (C₁-C₄)acylamino, carboxy, (C₁-C₄)alkoxycarbonyl, aminocarbonyl, mono- or di-(C₁-C₄)alkylaminocarbonyl, amino(C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl or halo(C₁-C₄)alkyl;
 - ♦ a phenyl radical disubstituted with a substituent R₂, R₂ being a halogen or a hydroxy, methyl, ethyl, (C₃-C₆)alkyl, (C₁-C₄)alkoxy or trifluoromethyl group and with a substituent X, X being as defined above;
 - ♦ a 1-naphthyl or 2-naphthyl radical;

- ♦ a 1-naphthyl or 2-naphthyl radical substituted in positions 5, 6, 7 and/or 8 with one or two hydroxyl groups, one or two (C₁-C₄)alkoxy groups or a 6,7-methylenedioxy group;
- or Z'' is hydrogen and Z and Z' represent, each independently, a non-substituted or mono-, di- or tri-substituted phenyl group;
- or ~~of one of its~~ a pharmaceutically acceptable salts and solvates;
- ~~for the preparation of pharmaceutical compositions capable of increasing circulating and cellular and extracellular levels of TGF- β_1~~ salt or solvate thereof other than a compound in which each of Z' and Z'' is hydrogen and Z is 1-naphthyl or 2-naphthyl.

Claims 2-18: Cancelled

Claim 19. (Currently amended): A compound selected from 1-[2-(6,7-methylenedioxy-naphth-2-yl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine, 1-[2-(4-cyclohexenylphenyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and 1-[2-(biphenyl-4-yl)ethyl]-4-(2-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine ~~and their~~ or a pharmaceutically acceptable salts and solvates salt or solvate thereof.

Claim 20. (New) A pharmaceutical composition comprising a compound according to Claim 19 and a pharmaceutically acceptable carrier.

Claim 21. (New) A method for the treatment of pathologies linked to an abnormal apoptotic activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 19.